Drugs / 99mTc-glucarate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00614354 | Oct 2008 → Sep 2010 | acute coronary syndrome | Molecular Targeting Technologies, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 99mTc-glucarate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00614354 ↗ |
| Known as | Technetium Glucarate | “The purpose of this clinical trial is to study the ability of a radioactive drug called "Technetium Glucarate" to detect whether the cause of chest pain in patients entering...” NCT00614354 ↗ |
| Modality | Diagnostic / imaging agent | “After one or two hours the patient will undergo an imaging procedure to detect if the drug has accumulated in the heart.” NCT00614354 ↗ |
| Route | Intravenous | “The drug will be injected intravenously.” NCT00614354 ↗ |